Molecular Epidemiology of Human Papillomavirus Infection Among Chinese Women With Cervical Cytological Abnormalities.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet ISSN: 2296-2565 (Electronic) Linking ISSN: 22962565 NLM ISO Abbreviation: Front Public Health Subsets: MEDLINE
    • Publication Information:
      Original Publication: Lausanne : Frontiers Editorial Office
    • Subject Terms:
      Papillomavirus Infections*/epidemiology ; Papillomavirus Infections*/genetics ; Uterine Cervical Neoplasms*/diagnosis ; Uterine Cervical Neoplasms*/epidemiology; Adult ; Aged ; China/epidemiology ; Cross-Sectional Studies ; Early Detection of Cancer ; Female ; Humans ; Molecular Epidemiology ; Papillomaviridae/genetics
    • Abstract:
      Background: Virtually all invasive cervical cancers are caused by persistent genital human papillomavirus (HPV) infection. Therefore, HPV-based screening becomes an essential tool as one of the cervical prevention strategies to reduce the disease burden. Population-specific epidemiologic information on HPV infection among women with cytological abnormalities is essential to inform the strategy of HPV-based screening programme. The study also explored the presence of cutaneous HPV types (Beta-β and Gamma-γ) in cervical infections.
      Methods: A cross-sectional study on Chinese women aged ≥25 years who were referred to public specialist out-patient clinics for colposcopy or further management of cervical cytological abnormalities were recruited between 2015 and 2016 in Hong Kong. HPV was detected and typified by the novel PCR-based Next-Generation Sequencing (NGS) strategies.
      Results: The overall HPV infection rate was 74% and detected in 222 of the 300 respondents, with the prevalence of cutaneous HPV infection being 2.3%. The overall prevalence of HPV infection among women with current cytological abnormalities was 79.1% (197/249). The age-specific prevalence of HPV (any-type HPV infection) among women with cytological abnormalities reached the first peak with 87.9% in the age group of 35-39 years and gradually declined to 56.0% at 55-59 years. While a second peak occurred at 65 years or above (92.9%). HPV58 (13.7%), HPV52 (11.7%), HPV53 (11.2%), HPV16 (10.0%), HPV18 (5.2%), and HPV51 (5.2%) were the top five high-risk HPV genotypes among women with cytological abnormalities. Any-HPV type infection was significantly associated with an abnormal cervical smear (OR = 3.7; 95% CI 2.0-7.1), and high-risk HPV infection was also significantly associated with an abnormal cervical smear (OR = 6.3; 95% CI 3.0-13.5).
      Conclusion: New evidence on the second peak of HPV infection at ≥65 years old suggests the necessity to review the current guideline for the cervical screening program extending to age 65 and above. Moreover, the high prevalence of two HPV genotypes-high-risk HPV51 and potential high-risk HPV53, among women with cytological abnormalities-suggests further research work is needed to confirm the contributory role of HPV51 and HPV53 in cervical cancer and the need for inclusion in the next generation of the HPV vaccine.
      Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
      (Copyright © 2022 Wong, Cheung, Chen, Wong, Yeung, Yau and Chan.)
    • References:
      Curr Opin Virol. 2017 Oct;26:56-62. (PMID: 28778034)
      J Virol. 2019 Mar 21;93(7):. (PMID: 30700603)
      J Med Virol. 2009 Sep;81(9):1635-44. (PMID: 19623668)
      CA Cancer J Clin. 2012 May-Jun;62(3):147-72. (PMID: 22422631)
      J Infect Dis. 2017 Jul 1;216(1):92-96. (PMID: 28549147)
      Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):553-60. (PMID: 23549399)
      J Cancer Prev. 2016 Jun;21(2):104-9. (PMID: 27390739)
      J Infect Dis. 2002 Jan 1;185(1):28-35. (PMID: 11756978)
      Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. (PMID: 23199969)
      Int J STD AIDS. 2014 Dec;25(14):1013-21. (PMID: 24648316)
      Front Cell Infect Microbiol. 2020 Jun 09;10:234. (PMID: 32582561)
      Oncol Lett. 2016 Jul;12(1):601-610. (PMID: 27347187)
      Ann Transl Med. 2016 Aug;4(15):276. (PMID: 27570770)
      Int J Cancer. 2017 Aug 15;141(4):664-670. (PMID: 28369882)
      Front Oncol. 2020 Apr 07;10:449. (PMID: 32318343)
      Int J Cancer. 2010 Jan 1;126(1):297-301. (PMID: 19588497)
      Infect Agent Cancer. 2015 Mar 02;10:7. (PMID: 25737740)
      Int J Cancer. 2012 Aug 1;131(3):692-705. (PMID: 21976212)
      Virology. 2013 Oct;445(1-2):224-31. (PMID: 23928291)
      J Infect Dis. 2018 Jul 2;218(3):388-397. (PMID: 29982800)
    • Contributed Indexing:
      Keywords: HPV genotypes; HPV prevalence; cervical cancer screening; cervical neoplasia; cytological abnormalities
    • Publication Date:
      Date Created: 20220603 Date Completed: 20220606 Latest Revision: 20220716
    • Publication Date:
      20240105
    • Accession Number:
      PMC9152134
    • Accession Number:
      10.3389/fpubh.2022.820517
    • Accession Number:
      35655449